Trump Executive Order on Separate MMR Shots Lacks Evidence, Risks Lower Uptake

The order designates 11 diseases for routine vaccination while shifting hepatitis A/B, rotavirus, meningococcal, influenza, and COVID-19 vaccines to high-risk or shared-decision categories. It directs HHS to develop separate measles, mumps, and rubella products. A cohort study of 2.5 million U.S. children published in JAMA found no association between MMR timing before age 2 and subsequent autism diagnosis, consistent with prior meta-analyses in The Lancet and NEJM.

Combined MMR has historically achieved higher coverage than separate components, correlating with reduced measles incidence in observational data from state surveillance systems. Past policy shifts emphasizing parental choice have preceded localized outbreaks when uptake fell below 92-95 percent thresholds. The executive order acknowledges state authority over school mandates yet sends conflicting signals that may erode confidence without altering legal requirements.

HHS under Secretary Kennedy is tasked with reassessing schedules and making monovalent vaccines available. Pediatric groups note that fragmented dosing increases missed opportunities and visit burden, patterns observed in pre-combination era records. Next observational studies must track state-level coverage changes and outbreak incidence over 24-36 months to quantify any effects.